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Abstract: Chemical  analysis  of  the  Mediterranean  ascidian  Polyandrocarpa  zorritensis 
(Van  Name  1931)  resulted  in  the  isolation  of  a  series  of  molecules  including  
two  monoindole  alkaloids,  3-indolylglyoxylic  acid  (3)  and  its  methyl  ester  (4),  
4-hydroxy-3-methoxyphenylglyoxylic acid methyl ester (1) and a new alkaloid we named 
zorrimidazolone  (2).  The  structure  of  the  novel  compound  2  has  been  elucidated  by 
spectroscopic  analysis  and  bioactivity  of  all  compounds  has  been  investigated. 
Zorrimidazolone (2) showed a modest cytotoxic activity against C6 rat glioma cell line.  
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1. Introduction 
Colonial ascidians are one of the most important marine bio-resources for new bioactive substances 
and this justifies the considerable interest shown by chemists and pharmacologists in this class of 
marine invertebrates. Moreover, a comprehensive understanding of their secondary metabolites and/or 
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their distribution among species could give further precious information. It could shine a light, for 
example, on the role of these metabolites in survival and adaptation of the invertebrates in diverse 
habitats as well as on the influence of the presence of chemically defended species on the development 
of benthic marine communities. As a part of our continuing search for new bioactive compounds from 
Mediterranean ascidians, we have investigated the stolidobranch ascidian Polyandrocarpa zorritensis 
(Van Name 1931). This is a non-indigenous ascidian in the Mediterranean Sea; it was indeed originally 
discovered and described in Peru and, later found in the northern Mediterranean in the summer of 
1974 [1]. Subsequently, in 1986, the species was found in the eastern Mediterranean [2] and, more 
recently (June 2001), in the harbor of Taranto (South Italy), where colonies developed vigorously on 
all hard substrata in shallow water and now represent one of the most important elements of the local 
fouling community [3]. We have now examined specimens of P. zorritensis collected in the bay of 
Taranto. This study resulted in the isolation of four compounds: 4-hydroxy-3-methoxyphenylglyoxylic 
acid methyl ester (1), a new alkaloid named by us as zorrimidazolone (2), 3-indolylglyoxylic acid (3) 
and its methyl ester (4). The new metabolite 2 belongs to the 2-aminoimidazolone class of marine 
metabolites,  which  have  been  predominantly  isolated  from  Axinella  and  Agelas  marine  sponges  
and  very  rarely  found  in  the  ascidians.  The  compounds  from  this  class  isolated  from  
ascidians  are  the  N,N-dimethylaminoimidazolone  found  in  Dendrodoa  grossularia  [4,5]  and  the  
polyandrocarpamines A and B in a Fijian Polyandrocarpa sp. [6]. 3-Indolylglyoxylic acid (3) and  
4-hydroxy-3-methoxyphenylglyoxylic  acid  methyl  ester  (1)  have  been  reported  as  synthetic 
intermediates [7,8] but their occurrence in any natural source has never been reported. Compound 4 
has also been reported as an intermediate in the synthesis of natural products [9,10] and recently found 
in the methanol extract of a marine sponge [11]. In fact, compounds 1 and 4 are presumed to be 
artifacts due to the use of methanol during the isolation procedures. 
The effect of compounds 1–4 on H9c2 (rat cardiac myoblast), HeLa (cervical cancer), and C6 (rat 
glioma) cells was investigated by evaluation of cell growth and viability.  
2. Results and Discussion  
2.1. Isolation and Structure Elucidation of Compounds 1–4 
Freeze-dried  specimens of  P.  zorritensis  were  exhaustively  extracted  at  room  temperature  with 
methanol and, subsequently, with chloroform. Combined extracts were then partitioned between water 
and ethyl acetate and, subsequently, between water and butanol. Both ethyl acetate and butanol soluble 
material were subjected to flash chromatography on a normal phase and on a reverse C18 bonded silica 
column, respectively. Subsequent purifications of the obtained fractions by reverse and normal phase 
HPLCs  yielded  compounds  1–4  in  the  pure  state.  Compounds  3  and  4  were  easily  identified  by 
comparison of their spectroscopic properties with those reported in literature [7,11]. Ester 1, as well  
as  the  corresponding  4-hydroxy-3-methoxyphenylglyoxylic  (vanilloylformic)  acid,  have  been  very 
recently reported as intermediates in the preparation of resiniferatoxin analogues [8]. Moreover, early 
syntheses of vanilloylformic acid are reported [12–14], however no spectroscopic data useful for the 
identification  of  1  were  available.  The  structure  of  this  compound,  and  new  compound  2,  was 
established by NMR spectroscopic analysis (Table1). Mar. Drugs 2011, 9  
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Table 1. 
1H and 
13C NMR data of compounds 1 and 2. 
Pos.  1 
a    2 
b   
  δH (mult., J in Hz)  δC  δH (mult., J in Hz)  δC 
1    164.2     
2    184.4    170.5 
4        189.9 
5        91.9 
1′    125.3    129.2 
2′  7.59 (d, 1.7)  110.6  7.05 (d, 1.7)  110.9 
3′    147.0    149.1 
4′    152.2    148.2 
5′  6.99 (d, 8.1)  114.3  6.79 (d, 8.1)  116.1 
6′  7.61 (dd 8.1, 1.7)  126.8  6.71 (dd 8.1, 1.7)  119.3 
10    -     
11    -     
-OCH3  3.98 (s)  56.1   3.67 (s)  56.3 
-CO2CH3  3.96 (s)  52.6    - 
-NMe    -  2.81 (s)  26.3 
-OH  6.24 (s)       
a Data recorded in CDCl3; 
b Data recorded in CD3OD. 
The ESI mass spectrum (positive ion mode) of compound 1 displayed ion peaks at m/z 211, 233, 
and 249 corresponding to [M + H]
+, [M + Na]
+, and [M + K]
+, respectively. The molecular formula 
C10H10O5 was established by HRESIMS analysis on the [M + H]
+ peak (m/z = 211.0615, calculated 
value: 211.0606) and implied six unsaturation degrees. The 
13C NMR spectrum displayed signals for 
all the ten carbons, which were identified, on the basis of HSQC data and of their chemical shift 
values, as two methyls linked to heteroatoms, three sp
2 methines, three sp
2 unprotonated carbons, and 
two carbonyls (see Table 1); these two latter signals accounted for two of the six unsaturation degrees 
indicated. The 
1H NMR spectrum (CDCl3) of 1 contained three aromatic signals at δ 6.99 (1H, d,  
J = 8.1), 7.59 (1H, d, J = 1.7) and 7.61 (1H, dd, J = 8.1, 1.7); the presence in 1 of a 1,2,4-trisubstituted 
benzene ring was thus deduced, on the basis of the coupling constant pattern of the above proton 
signals and according to 
13C spectrum data, and the remaining four unsaturations were accounted for. 
Additional features of the proton spectrum of 1 were two methoxyl signals at δ 3.98 and δ 3.96, and a 
signal at δ 6.24 (1H, s) exchangeable in D2O. The latter signal, attributable to the proton of a phenol 
function, was correlated in the HMBC spectrum to both the down field shifted unprotonated aromatic 
carbons at δ 147.0 and 152.2, as well as to the methine carbon at δ 114.3; besides, the methoxyl signal 
at δ 3.98 showed a long-range coupling with the carbon signal at δ 147.0. Thus, the presence of two 
oxygenated functions (hydroxyl and methoxyl) ortho-orientated on the benzene ring was deduced. The 
nature of the remaining substituent as well as its location on the aromatic ring was deduced by analysis 
of  HMBC  and  ROESY  data.  The  methoxyl  signal  at  δ  3.96  was  long  range  coupled  to  both  the 
carbonyls  at  δ  164.2  and  184.4;  the  latter  carbonyl  signal  showed  HMBC  correlations  with  the 
aromatic  proton  signals  at  δ  7.59  (H-2′),  showing  only  a  small  meta-coupling,  and  7.61  (H-6′),  
ortho-coupled to the signal at δ 6.99 (H-5′). This information suggested an oxoacetic acid methyl ester 
moiety to be linked at the benzene ring, according to the molecular formula and the nature of the Mar. Drugs 2011, 9  
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remaining NMR signals. Moreover, a strong correlation observed in the ROESY spectrum between the 
methoxyl signal at δ 3.98 (MeO-) and the aromatic proton at δ 7.59 (H-2′) was observed and, therefore, 
the structure of compound 1 was established as methyl 2-(4-hydroxy-3-methoxyphenyl)-2-oxoacetate. 
ESI mass spectrum (positive mode) of zorrimidazolone (2) showed ion peaks at m/z 252 and 274, 
corresponding to [M + H]
+ and [M + Na]
+, respectively; the molecular formula was shown to be 
C11H13N3O4 by HRESIMS analysis on the [M + H]
+ peak (m/z = 252.0995, calculated value: 252.0984) 
and indicated seven unsaturation degrees. According to mass data, 
13C NMR spectrum (CD3OD) of 2 
contained  11  signals  which,  on  the  basis  of  HSQC  data,  were  sorted  as  two  methyls,  three  sp
2 
methines,  one  sp
3  as  well  as  five  sp
2  quaternary  carbons.  Proton  and 
13C  NMR  spectra  (CD3OD, 
Table 1), interpreted on the basis of HSQC and HMBC data, revealed the presence in 2 the same  
4-hydroxy-3-methoxyphenyl moiety as in 1, indicating the different structural moiety at C-1′. This 
portion of the molecule accounted for four unsaturation degrees, leaving three unsaturations for the 
remaining C4H6N3O2 subunit. This unidentified sub-structure contained three quaternary carbons, two 
of  them  attributable  to  carbonyls  (δ  170.5  and  189.9),  and  one  N-linked  methyl  group  (δC  26.3; 
δH 2.81); hence, one ring was present in this subunit and the three remaining hydrogen atoms were 
attached to heteroatoms. In the 
1H NMR spectrum of 2 recorded in DMSO-d6 (see Experimental), in 
addition to the phenol signal at δ 7.01, two exchangeable signal at δ 5.41 and 7.48 were visible. The 
latter signal was correlated in the ROESY spectrum (DMSO-d6) to the N-methyl signal at δ 2.65. The 
location of the methyl group at N-1 was deduced by the observation of the correlations between the 
signal at δ 2.65 and the two aromatic protons at δ 6.84 (H-2′) and 6.55 (H-6′); a weaker correlation to 
the proton at δ 6.73 (H-5′) was also observed. The chemical shift value (δ 91.9) of the third sp
3 
unprotonated carbon present in this subunit was characteristic of a carbinolamine carbon. On the basis 
of its HMBC (CD3OD) correlations with the aromatic methine protons at δ 7.05 and 6.71, this carbon 
was assumed to be attached to the aromatic ring. Two further informative correlations were present in 
the  HMBC  spectrum  (CD3OD)  of  2  between  the  N-linked  methyl  group  (δ  2.81)  and  the  carbon 
resonances at δ 91.9 (C-5) and 170.5 (C-2). The above NMR data as a whole suggested the presence of 
a 2-amino-5-hydroxy-1-methylimidazolone moiety linked to the 2-methoxyphenol unit, according to 
mass information and endorsed by comparison with data reported in literature for other aminoimidazolone 
compounds  [5,6]. Thus, the structure of zorrimidazolone (2) was defined as reported in Figure 1. 
However,  it  should  be  pointed  out  that  the  reported  tautomeric  form  was  deduced  by  NMR 
experiments recorded in DMSO-d6 and that the predominance of another tautomer in different solvents 
cannot be excluded. In spite of the presence of the stereogenic center at C-5, zorrimidazolone did not 
show optical rotation either Cotton effects on the CD spectrum (MeOH). 
Aminoimidazolone  ring-containing  metabolites,  like  zorrimidazolone,  have  been  reported  from 
other ascidians, also belonging to Polyandrocarpa genus [6]. In particular, compounds structurally 
related to zorrimidazolone (6–8) have been isolated from Polycarpa clavata and P. aurata and they 
were hypothesized to be artifacts derived from polycarpine (5) (Figure 2). In the light of the above 
report, we considered that zorrimidazolone could derive from a hypothetic parent dimeric disulfide 
alkaloid,  as  compounds  6–8  from  polycarpine  (5).  However,  this  possibility  could  be  confidently 
excluded since (i) in the isolation procedure of 2 we didn’t use silica and basic condition which very 
probably were the causative agent of the degradation of polycarpine; (ii) in the extract of P. zorritensis 
no trace was detected of the putative parent disulfide nor of a thioxoimidazolone compound. Mar. Drugs 2011, 9  
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Figure 1. Structures of compounds 1–4. 
 
Figure 2. Structures of polycarpine (5) and related compounds (6–8). 
 
Finally, the optical inactivity of 2, suggesting its racemic nature, is strongly indicative that 2 could 
be in equilibrium  with the guanidinic open form (see Scheme 1). Interestingly, the occurrence of 
guanidinic derivatives of methoxyphenols from ascidians of the genus Polycarpa have been recently 
reported [15]. 
Scheme 1. Equilibrium of compound 2 with the guanidinic open form. 
 
2.2. Biological Activities of Compounds 1–4 
Bioactivity of compounds 1–4 was investigated on H9c2 rat cardiac myoblast cells, HeLa cervical 
cancer cells and C6 rat glioma cells by evaluation of cell growth and viability. To this aim, the cells 
were treated for 48 h with various concentrations of each compound and then the cell count and the Mar. Drugs 2011, 9  
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MTT assay were performed. The results, reported in Table 2 as IC50 values, showed that, with the 
exception of compound 1, compounds 2, 3 and 4 exhibited a selective and concentration-dependent 
cytotoxic activity toward the C6 cells, whereas no relevant cytotoxicity was observed against HeLa 
and H9c2 cells. Zorrimidazolone (2) showed the higher cytotoxic effect versus C6 cells leading to a 
decrease of viability of about 60% when administrated at 250 µM ; its IC50 value against C6 cells was 
within the micromolar range (~150 µ M), which is generally considered as a moderate cytotoxic activity.  
Table 2. C6 (rat glioma) cells growth inhibition by compounds 1–4. 
Compound  IC50 (µ M) 
a 
1  >10
3 
2  155 ±  13 
3  314 ±  17 
4  305 ±  15 
a  IC50  values  are  expressed  as  mean  ±   SEM  of  three  independent  experiments  conducted 
in triplicates. 
The  rat  C6  cells  line  represent  a  useful  in  vitro  model  for  studying  gliomas.  Although  many 
advances in antineoplastic therapy have taken place, many malignant gliomas are resistant to many 
pharmacological treatments [16]. Therefore, zorrimidazolone could be of interest in the developing of 
potential gliomas antiproliferative molecules. 
3. Experimental Section 
3.1. General Experimental Procedures 
ESI mass spectra were recorded on a hybrid quadrupole-TOF mass spectrometer in MeOH. The 
spectra were recorded by infusion into the ESI source using MeOH as the solvent. HRESIMS (positive 
mode) were performed on a Thermo LTQ Orbitrap XL mass spectrometer. Optical rotations were 
measured with a Perkin-Elmer 192 polarimeter at 589 nm using a 10 cm microcell. ECD spectra were 
recorded on a J-710 spectropolarimeter (Jasco, Tokyo, Japan) equipped with a J-710 for Windows 
software (Jasco). 
1H (700 MHz and 500 MHz) and 
13C (175 MHz and 125 MHz) NMR spectra were 
recorded on a Varian INOVA spectrometer; chemical shifts were referenced to the residual solvent 
signal (methanol-d4: δH 3.31, δC 49.0; chloroform-d: δH 7.26, δC 77.0). Homonuclear 
1H connectivities 
were  determined  by  COSY  and  TOCSY  (mixing  time  100  ms)  experiments.  Through-space 
1H connectivities were evidenced using a ROESY experiment with a mixing time of 500 ms. Two and 
three bond 
1H-
13C connectivities were determined by gradient 2D HMBC experiments optimized for  
a J2,3 of 8 Hz.  
3.2. Collection, Extraction and Isolation 
Specimens of P. zorritensis were collected in the bay of Taranto and kept frozen until used. Freshly 
thawed  organisms  (47.078  g  dry  weight  after  extraction)  were  exhaustively  extracted  at  room 
temperature with methanol (3 ×  1.5 L) and, subsequently, with chloroform (3 ×  1.5 L). The extracts 
were combined and concentrated in vacuo; the resulting aqueous residue was then partitioned between Mar. Drugs 2011, 9  
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water and ethyl acetate. The organic layer was removed and the water soluble portion was further 
partitioned  in  butanol.  The  ethyl  acetate  soluble  material  (3.42  g  after  solvent  evaporation)  was 
subjected to a gradient silica gel MPLC (hexane→AcOEt→MeOH). The 50% Hexane/50% AcOEt 
fraction was evaporated to dryness under reduced pressure and chromatographed by HPLC on a silica 
column (LUNA 5 μm, 250 ×  4.60 mm), using 70% Hexane/30% AcOEt as the eluent at a flow rate of 
0.8 mL/min. This afforded pure compound 1 (2.1 mg) and compound 4 (1.7 mg). 
Separation of the butanol soluble material (7.77 g after solvent evaporation) was achieved by a  
C18 bonded silica MPLC eluting with a step gradient of MeOH in H2O from 10% to 100%. The  
fast-running fraction, eluted with 90% H2O/10% MeOH, was first subjected to a preparative reverse 
phase HPLC on a Kromasil 10 μm column (250 ×  10 mm), eluting with 95% H2O/5% MeOH at a flow 
rate of 2 mL/min, to give a mixture of zorrimidazolone and small amounts of other polar metabolites. 
The mixture was further purified by HPLC on a Synergie 4 µ POLAR-RP 80A column (250 ×  4.60 mm) 
using 98% H2O/2% MeOH as the eluent at a flow rate of 1 mL/min; this afforded zorrimidazolone in 
pure form (1.1 mg). 
The MeOH 100% fraction was separated by reverse phase HPLC (LUNA 3 µ m, C18, 150 ×  4.60 mm), 
using 65% H2O/35% MeOH as the eluent at a flow rate of flow 0.4 mL/min); this yielded compound 3 
in pure form (1.5 mg). 
3.3. Methyl 2-(4-Hydroxy-3-methoxyphenyl)-2-oxoacetate (1)  
Yellow  amorphous  powder.  HRESIMS  (positive  ion  mode):  m/z  =  211.0615  [M  +  H]
+,  the 
molecular formula C10H11O5 requires 211.0606. 
1H and 
13C NMR data (CDCl3): see Table 1. 
1H NMR 
data (DMSO-d6) 7.43 (overlapped, 1H, H-2′), 6.95 (d, 1H, J = 8.1 Hz, H-5′), 7.45 (overlapped, 1H,  
H-6′), 3.84 (s, 3H, -OCH3), 3.91 (s, 3H, -CO2CH3), 10.6 (s, 1H, -OH). 
3.4. Zorrimidazolone (2)  
Pink amorphous powder. HRESIMS (positive ion mode): m/z = 252.0995 [M + H]
+, the molecular 
formula C11H14N3O4 requires 252.0984; 
1H and 
13C NMR data (CD3OD): see Table 1. 
1H NMR data 
(DMSO-d6): 6.84 (d, 1H, J = 1.8 Hz, H-2′), 6.73 (d, 1H, J = 8.2 Hz, H-5′), 6.55 (dd, 1H, J = 1.8–8.2 Hz, 
H-6′), 3.74 (s, 3H, -OCH3), 2.65 (s, 3H, -NCH3), 7.01 (s, 1H, -OH-4′), 5.41 (s, 1H, -OH-5), 7.48  
(s, 2H, -NH2). 
3.5. Biological Activity 
Biological activity of the isolated compounds was investigated on H9c2 rat cardiac myoblast cells, 
HeLa cervical cancer cells and C6 rat glioma cells by evaluation of cell growth and viability. Cells 
were grown in Dulbecco’s modified Eagle’s medium (DMEM) containing high glucose (4.5 g/L) and 
supplemented with 10% fetal bovine serum (FBS), L-glutamine (2 mM), penicillin (100 units/mL) and 
streptomycin (100 μg/mL) according to ATCC recommendations. Cells were cultured at 37 °C  in a 
humidified 5% CO2 atmosphere. For experimental purposes, cells were washed, collected by trypsine 
and then inoculated in a 96-microwell culture plates at density of 10
4 cells/well. Cells were allowed to 
grow for 24 h, then the medium was replaced with fresh medium and cells were treated for further 48 h Mar. Drugs 2011, 9  
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with test compounds. In detail, 1 or 2 µL  of DMSO solutions containing the test compounds were 
added to cell culture medium to give various concentration; 1 or 2 µL  of DMSO alone (vehicle) were 
added into control cells (0.5 and 1% v/v final concentrations, respectively).  
Cell viability was determined by the trypan blue dye exclusion test. After treatments, the medium 
was removed and the cells were washed twice with PBS buffer solution and then incubated with a 
trypsin-EDTA solution at 37 °C  for 5 min. Trypsin was inactivated by re-suspending the cells in 
medium containing 10% FBS. The cells were pelleted at 250×  g and resuspended in PBS. Viable cells, 
cells that excluded 0.4% trypan blue, were then counted with a hemocytometer. 
Concurrently, cell viability was evaluated with an MTT assay procedure, which measures the level 
of mitochondrial dehydrogenase activity using 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT) as substrate [17]. The assay was based on the redox ability of living mitochondria to 
convert dissolved MTT into insoluble formazan. Briefly, after treatments with the test compounds, the 
medium was removed and the cells were incubated with 20 µ L/well of an MTT solution (5 mg/mL) for 
1 h  in  a  humidified  5%  CO2  incubator  at  37  ° C.  The  incubation  was  stopped  by  removing  the 
MTT solution and adding 100 µ L/well of DMSO to solubilize the formazan. The absorbance was  
monitored at 550 nm by using a Perkin-Elmer LS 55 Luminescence Spectrometer (Perkin-Elmer Ltd., 
Beaconsfield, UK) [18]. 
The calculation of the concentration required inhibiting the net increase in the 48 h cell count and 
viability by 50% (IC50) is based on plots of data carried out in triplicates and repeated three times.  
IC50 values were obtained using a dose response curve by nonlinear regression using a curve fitting 
program, GraphPad Prism 5.0, and are expressed as mean ±  SEM. 
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